FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
Summary
The Food and Drug Administration has issued a safety warning regarding popular weight loss medications. Regulators stated that these treatments may increase the risk of a rare eye condition capable of causing permanent blindness. Consequently, manufacturers of these drugs will be required to update their product labeling to include this information.
The Food and Drug Administration is warning that popular obesity drugs—including Ozempic, Wegovy, Zepbound, and Mounjaro—may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss. In a drug safety communication Monday, the FDA said it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on…
Source: Read the full story at Ars Technica - All content